Autopsy report · NCT01284166
Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Cause of deathFunding or business, also slow enrollment
“Study was never initiated due to company decision. No study subjects were ever enrolled or treated.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 3
- Sponsor
- Allergan
- Sponsor type
- Industry
- Conditions
- Glaucoma; Ocular Hypertension
- Interventions
- dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution
- Participants
- 0
Trials that died the same way
- Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne
“Study was never initiated due to company decision. No study subjects were ever enrolled or dosed.” - A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer
“Due to a strategic decision by the company, the study will not proceed, and no subjects have been enrolled to date.” - Efficacy of Using Solum IV and BMC With GFC in TLIF
“Study was never initiated due to contracting issues” - Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome
“This study was terminated early due to company decision. Part B was never conducted.” - A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression
“Study did not receive funding and was never carried out.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.